Cannabinoid receptors mediate the actions of ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) 1 and other cannabimimetic ligands (1). To date, two types of cannabinoid receptors have been discovered, CB1 (2, 3) and CB2 (4). A splice variant of CB1, termed CB1A, has also been reported (5). Apart from a recent report of CB2 in mouse cerebellum (6), CB1 has been the only cannabinoid receptor found in brain. All cannabinoid receptors discovered to date belong to the superfamily of G-protein-coupled receptors (3, 4); their effectors include inhibition of adenylyl cyclase (7, 8), inhibition of calcium influx (9), and activation of inwardly rectifying potassium channels (10, 11). The physiological actions of cannabinoid ligands have been shown to be mediated through the activation of pertussis toxin-sensitive G-proteins (G i ␣ and G o ␣ subtypes) (7, 12), although some effects have been implicated via G s ␣ as well (13, 14) .
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G-proteins are heterotrimeric proteins that transduce the agonist binding signal from G-protein-coupled receptors to effectors (15, 16) . Upon activation by an agonist-occupied receptor, the ␣ subunit of a G-protein (G␣) releases bound GDP, binds a molecule of GTP, and dissociates from the G-protein ␤␥ subunit complex. Both G␣ and ␤␥ subunits act upon effectors until G␣ cleaves the bound GTP to GDP by its intrinsic GTPase activity, and G␣ re-associates with a ␤␥ dimer (15, 16) . The cycle is then complete, and the heterotrimeric G-protein is able to be activated again. Receptors act catalytically, as one receptor can activate multiple G-proteins (17) (18) (19) . The activation and dissociation of the G-protein subunits occur very rapidly and thus do not appear to be rate-limiting steps in the signal transduction cascade (20) . However, since the actions of G-protein-coupled receptors are mediated strictly via the activation of G-proteins, this step plays a key role in determining overall agonist efficacy (21) and may be the most relevant step in measuring agonist efficacy at G-protein-coupled receptors (22) .
Agonist-stimulated binding of the hydrolysis-resistant GTP analog, [ 35 S]GTP␥S, to G-protein ␣ subunits measures receptor activation of G-proteins in purified and reconstituted systems (23) , native cell membrane preparations (24) , and brain sections (25) . The present study focuses on three aspects of the role of GDP in the agonist-stimulated [ 35 S]GTP␥S binding assay. First, GDP has been shown to decrease basal [ 35 S]GTP␥S binding and allow detection of agonist stimulation. The requirement for micromolar concentrations of GDP to observe agonist effects in native membrane preparations has been reported consistently in every system for which agonist-stimulated [ 35 S ]GTP␥S binding has been demonstrated (24, 26 -28) . Second, GDP has been reported to modulate the kinetics of [ 35 S]GTP␥S binding. The presence of micromolar concentrations of GDP was shown to decrease the magnitude and rate of [ 35 S]GTP␥S binding to purified and reconstituted G-proteins (23) . However, early reports of [ 35 S]GTP␥S binding to purified G-protein G i ␣ (29) and G o ␣ (30) subunits concluded that this binding is essentially irreversible in the presence of millimolar concentrations of Mg 2ϩ , which is also required for agonist stimulation of [ 35 S]GTP␥S binding (31) . Therefore, a problem frequently noted for [ 35 S]GTP␥S binding is that it is performed under non-equilibrium conditions, thus complicating interpretation of the results.
Finally, GDP has been shown to play an important role in determining agonist efficacy for the stimulation of [ 35 S]GTP␥S binding. In the adenosine A1 receptor system, a full agonist was shown to be maximally effective for the stimulation of [ 35 S ]GTP␥S binding at a higher concentration of GDP than a partial agonist (32) . Similar results were found in the mu opioid system, where increasing the concentration of GDP increased relative efficacy differences among agonists (33) . In order to determine whether GDP plays similar roles in modulating cannabinoid agonist efficacy, it is necessary to compare [ 35 S]GTP␥S binding stimulated by agonists of different efficacies. Previous studies which showed that ⌬ 9 -THC (34, 35) , CP 55940 (36) , and anandamide (37) (38) (39) are each partial agonists provide an effective starting point to examine this question.
The present study explores these three aspects of GDP modulation of G-protein activation by cannabinoid agonists. The cannabinoid system is ideal for the study of G-protein activation in brain membranes, due to the very high levels of cannabinoid receptors (40) and cannabinoid-activated G-proteins (25) compared with other G-protein-coupled receptors in brain. These experiments provide evidence that cannabinoid agoniststimulated [ 35 S]GTP␥S binding is dependent on the agonistinduced decrease in G-protein affinity for GDP and that cannabinoid agonist efficacy for G-protein activation is determined by the magnitude of this decrease in affinity. Membrane Preparations-Rat cerebellar membranes were prepared in membrane buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, pH 7.4) and stored at Ϫ80°C as described previously (41) . For assays including anandamide, thawed membranes were pretreated with 50 M phenylmethylsulfonyl fluoride (PMSF) followed by centrifugation and homogenization of the pellet. All preparations were preincubated for 10 min at 30°C with 0.004 units/ml adenosine deaminase (Sigma) and assayed for protein content (42) before addition to assay tubes.
EXPERIMENTAL PROCEDURES

Materials-Male
[ 35 S]GTP␥S Binding-Assays were performed as described previously (41). Unless otherwise specified, 4 -15 g of cerebellar membrane protein were incubated for 2 h at 30°C in membrane buffer containing 0.1% (w/v) bovine serum albumin, 100 mM NaCl, 30 M GDP, and 0.05 nM [ 35 S]GTP␥S in a final volume of 1 ml, and nonspecific binding was determined with 30 M unlabeled GTP␥S. For association assays, membranes were added to assay tubes on ice, and assay tubes were transferred to a 30°C water bath at various times. Reactions were terminated in all tubes simultaneously by rapid filtration as described previously (41) . For dissociation assays, assay tubes were allowed to associate for 1 h (0 and 0.1 M GDP) or 2 h (3 and 30 M GDP) before the addition of 30 M unlabeled GTP␥S at various times; reactions were terminated as above.
Data Analysis-Unless otherwise indicated, binding parameters were determined by nonlinear regression analysis using JMP for Macintosh (SAS Institute, Cary, NC). Association parameters were fitted to Equation 1 (43 are the amounts of ligand bound to rapidly and slowly dissociating sites at time 0, and k 1 and k 2 are the dissociation rate constants (k Ϫ1 ) for the rapidly and slowly dissociating sites, respectively. Half-times for each site were calculated by dividing Ϫln(0.5) by the respective rate constants (k obs or k Ϫ1 ). EC 50 and E max values for each agonist were determined by fitting concentration-effect curves to Equation 3 . Fig. 1B . Nonlinear regression analysis of these data determined that neither GDP nor agonist affected the t1 ⁄2 values of either rate, but both increased the fraction of sites that displayed rapid dissociation. In the absence of GDP and agonist, only 14% of the 35 S]GTP␥S-binding sites and the effect of agonist on these sites, GTP␥S saturation experiments were performed after 2-h incubations in the presence and absence of a maximally effective concentration of WIN 55212-2 and 30 M GDP (Fig. 3 ). In the absence of GDP, [ 35 S]GTP␥S binding was biphasic, displaying both high (apparent K D ϭ 2.7 nM) and low (apparent K D ϭ 800 nM) affinity sites (Table II) . Addition of WIN 55212-2 had no effect on the apparent K D or B max of either site in the absence of GDP (Fig. 3A) . In the presence of 30 M GDP alone ( (Fig. 3B , inset, and Table II) , similar to previous results with mu and delta opioid agonists (19, 27, 33, 46) .
In addition to increasing the apparent affinity of G␣ for [ 35 S]GTP␥S, agonists have been reported to reduce the affinity of G␣ for GDP (15, 16, 23 (Fig. 3) , it also decreased the affinity of a fraction of GDPbinding sites (Fig. 4) . The effect of agonist on GDP affinity in , these data were re-plotted in a logarithmic fashion (Fig. 4B) . When plotted in this manner, it is clear that WIN 55212-2 had no effect on [ Relationship between GDP and Cannabinoid Agonist Efficacy-Previous studies have demonstrated differences in cannabinoid agonist efficacies by different methods. Since G-protein activation is the first step in the signal transduction cascade of G-protein-coupled receptors, it was of interest to measure cannabinoid efficacy by agonist-stimulated [
35 S]GTP␥S binding. Several cannabinoid ligands with different structural bases were selected including the following: ⌬ 9 -THC, the primary psychoactive constituent of marijuana; WIN 55212-2, a synthetic aminoalkylindole agonist; levonantradol, a potent ⌬ 9 -THC analog; CP 55940, a synthetic bicyclic compound; anandamide and methanandamide, an endogenous cannabinoid agonist and its esterase-resistant analog; and SR141716A, the CB1-selective antagonist.
To establish the relative efficacies of these agonists for 50 values) varied widely for these compounds. CP 55940 displayed the greatest potency with an EC 50 of 6.6 Ϯ 0.5 nM; levonantradol was next at 9.0 Ϯ 0.4 nM, followed by ⌬ 9 -THC at 87 Ϯ 42 nM, WIN 55212-2 at 160 Ϯ 38 nM, and methanandamide and anandamide at 320 Ϯ 26 and 390 Ϯ 96 nM, respectively (Fig. 5) . As previously shown for receptor binding (39) , pretreatment of the membranes with the irreversible esterase inhibitor PMSF greatly increased the potency of anandamide, since without PMSF pretreatment, anandamide stimulated [ 35 S]GTP␥S binding with an EC 50 of 1750 Ϯ 570 nM (data not shown). In contrast, none of the potencies or efficacies of the other agonists, including methanandamide, were significantly affected by PMSF pretreatment (data not shown).
Concentration-effect analysis revealed that these ligands produced a wide range of efficacies for G-protein activation in the [ 35 S]GTP␥S binding assay (Fig. 5) . WIN 55212-2 and levonantradol displayed the highest efficacies, and these two ligands were designated as full agonists. For this reason, results for other ligands were normalized to the amount of net agoniststimulated [ 35 S]GTP␥S binding obtained with a maximally effective concentration of levonantradol (1 M), which was defined as 100% within each experiment (Fig. 5) . Likewise, E max values obtained by nonlinear regression analysis for each agonist were normalized to the E max value obtained with levonantradol (Table IV) (Fig. 5) .
In other receptor systems, increasing the GDP concentration was reported to increase differences between full and partial agonists for stimulating [ 35 S]GTP␥S binding (32, 33) . Therefore, the relationship between GDP and cannabinoid agonist efficacy was directly explored using a few representative cannabinoid ligands. To determine whether the affinity of the low affinity GDP-binding site was related to the efficacy of the agonist, GDP competition curves were generated with 0.05 nM [ 35 S]GTP␥S in the presence and absence of maximally effective concentrations of these ligands. As described above (Table III) , GDP displaced [
35 S]GTP␥S binding with both high and intermediate affinity or high and low affinity in the absence or presence of agonist, respectively. Full biphasic analysis (Table  IV) indicated that the agonists had no significant effect on the K i values of high affinity GDP binding, which were all between 20 and 47 nM. In the absence of agonist, the low affinity GDPbinding sites had an intermediate K i value of 1.1 M; in the presence of agonist, the affinity of this low affinity GDP site depended on the agonist. ⌬ 9 -THC had no statistically significant effect on the low affinity GDP K i value (1.3 M), whereas the full agonists WIN 55212-2 and levonantradol produced low affinity GDP K i values of 8 M, and the partial agonist methanandamide produced a K i value of 6.6 M. (Table IV) .
The finding that these agonists decreased GDP affinity in proportion to their efficacies predicts that saturating concentrations of full agonists will be maximally effective for the stimulation of [ 35 S]GTP␥S binding at higher concentrations of GDP than saturating concentrations of partial agonists. This relationship is depicted in Fig. 6A where net agonist-stimulated [ 35 (Fig. 6B) , differences in percent stimulation among the agonists increased as the concentration of GDP was increased to an optimum level of approximately 100 M. Thus, at 0.1 M GDP there was little difference between the full and partial agonists, at 1 M GDP there was a significant difference between ⌬ 9 -THC and all of the higher efficacy agonists, and at 30 M GDP the efficacies of the high efficacy partial agonists CP 55940, anandamide, and methanandamide were different from the full agonists WIN 55212-2 and levonantradol (data for representative ligands are shown in Fig. 6B ). CP 55940 was Table IV ). These data show that agonists of high efficacy produced higher low affinity GDP K i values than agonists of lower efficacy. The correlation between these two parameters was highly significant (r ϭ 0.979, analysis of variance, p ϭ 0.0007). In contrast, there was no significant correlation (r ϭ 0.333, p ϭ 0.519) between E max values and high affinity GDP K i values obtained in the presence of each agonist (data not shown).
DISCUSSION
This study characterized several aspects of the role of GDP in the activation of G-proteins by cannabinoid receptors in brain membranes. In kinetics studies, [ 35 (29, 30) . This discrepancy might be explained by the lower ratio of G-protein ␤␥ to G␣ subunits in purified systems compared with those that may be present in native membranes (29, 30, 48, 49) . [ 35 S]GTP␥S binding to purified G o ␣ and G i ␣ exhibits both rapid and slow dissociation rates, and the ratio of slowly to rapidly dissociating sites is proportional to the concentration of Mg 2ϩ (50) . ␤␥ subunits increase the dissociation of [
35 S]GTP␥S from G␣, but this effect is inhibited by Mg 2ϩ , which inhibits ␤␥ coupling to G␣ (30, 50) . The present study found that upon addition of excess GTP␥S, cannabinoid agonist increased the ratio of rapidly to slowly dissociating [ 35 S]GTP␥S-binding sites by the same degree (62-86%) regardless of the concentration of GDP. It is possible that the agonist-induced increase in rapidly dissociating [ 35 S]GTP␥S binding was the result of the liberation of large amounts of ␤␥ by the agonist-accelerated binding of the unlabeled GTP␥S to G␣ subunits. The finding that GDP produced a slight increase in the ratio of rapidly dissociating [ 35 S]GTP␥S-binding sites is consistent with the fact that GDP increases the ratio of low affinity to high affinity [
35 S]GTP␥S-binding sites (Fig. 3) , which would be expected to display different dissociation rates.
In cerebellar membranes, basal and cannabinoid-stimulated [ 35 S]GTP␥S binding appeared to follow the characteristics of bimolecular reactions, allowing the data to be analyzed in the manner of traditional radioligand binding. However, any study involving the binding of guanine nucleotide analogs to G-proteins must consider the presence of pre-bound GDP. It has been shown that GDP remains bound to G␣ in high molar ratios even after purification of G␣ subunits (43 (Fig. 4) .
Concentration-effect curves comparing the relative efficacies of several cannabinoid agonists determined that WIN 55212-2 and levonantradol produced the highest E max values for the stimulation of [ 35 S]GTP␥S binding and are therefore referred to as full agonists. CP 55940 was a high efficacy partial agonist, confirming the results of a previous study (36) . Anandamide and methanandamide both acted as partial agonists, in agreement with previous studies demonstrating partial agonism for the inhibition of Ca 2ϩ currents (37) and adenylyl cyclase activity (38, 39) . As previously shown (34, 35) (6) , then the 700 nM K i of SR141716A at CB2 receptors (54) makes it possible that this inhibitory effect was mediated by CB2 receptors.
In agreement with results obtained in the mu opioid system, increasing the concentration of GDP between 0.1 and 100 M increased efficacy differences among agonists (33) . Significant stimulation of [
35 S]GTP␥S binding was observed only in this range of GDP concentrations. The slight and variable stimulation of [ 35 S]GTP␥S binding observed in the absence (or at nanomolar concentrations) of added GDP may have been due to agonist-induced release of pre-bound GDP on the G-proteins (43) .
A question that can be addressed by these data is which change in G-protein affinity is mediating agonist efficacy, i.e. is an increase in GTP(␥S) affinity the fundamental mechanism or is the agonist-induced increase in apparent GTP(␥S) affinity caused by a decrease in GDP affinity? These data suggest that the agonist-induced increases in the apparent affinity of [ 35 S]GTP␥S were due to decreases in the affinity of GDP, since (Fig. 3, lower panel, and Fig. 4 ; and Tables II and  III; and Fig. 8 ). The affinities of [ 35 S]GTP␥S for the three sites observed in the presence of 30 M GDP can actually be predicted based on the observed affinities for GDP and previous reports of the actual affinity of purified G␣ subunits for [ 35 S]GTP␥S. This prediction was made on the basis that the presence of a binding competitor will decrease the apparent affinity of a radioligand by an amount proportional to the ratio of the competitor's concentration and inhibition constant, according to a rearrangement of the Cheng-Prusoff equation: S]GTP␥S binding affinity that were induced by agonist were due to agonist-induced decreases in G-protein affinity for GDP. This is in agreement with studies of purified G o indicating that the primary mechanism of agonist activation is an increase in the dissociation rate and a decrease in the association rate of GDP (23) . Moreover, the correlation between agonist-induced K i values and agonist E max values (Fig. 7 and Table IV (55) .
Previous reports of the mechanisms of receptor activation of purified G-proteins have found that agonists induced G-proteins to release GDP, allowing GTP or [ 35 S]GTP␥S to bind to G-protein ␣ subunits (15, 16, 23) . Studies with adenosine receptors in membranes showed that the magnitude of agonistinduced release of [ 3 H]GDP from membranes corresponded to agonist efficacy (32) . In the current study, experiments measuring the effect of different cannabinoid agonists on GDP binding affinities indicated that the mechanism of agonist efficacy is the magnitude of the decrease in G-protein affinity for GDP. 35 S]GTP␥S exhibiting high apparent affinity and GDP exhibiting low affinity. The remaining binding sites that appear in the presence of agonist, which exhibit low apparent affinity for [ 35 S]GTP␥S and high affinity for GDP, appear to be present also in the absence of agonist, under basal conditions. The binding sites for each ligand that are apparent only in the absence of agonist both display intermediate affinities. Since the apparent affinities of [ 35 S]GTP␥S in the presence of GDP appear to depend on the affinity for GDP, it suggests the possibility that each ligand binds to the same three sites with reciprocal apparent affinities.
These results explain why increases in GDP concentration magnified differences in agonist efficacy in both the present study and in the mu opioid system (33) . Thus, the results of the present study appear to generalize to G-protein-coupled receptors based on similarities to previously published results from both purified and native membrane systems. It appears that the agonist-induced low affinity state of the G-protein for GDP is necessary and sufficient to explain agonist-induced stimulation of [ 35 S]GTP␥S binding by G-protein-coupled receptors.
